Among participants screened at admissions | Interventional period | Control period | p value |
---|---|---|---|
n = 147 patientsa | N = 86 patientsa | ||
Patients at a high risk (%) | 30 (20.4%) | 29 (33.7%) | 0.04 |
Median length of stay (days, IQR) | 2.8 (1.5–5.6) | 2.8 (1.7–7.1) | 0.67 |
nEcESBL-PE carriers | 10 (6.8%) | 8 (9.3%) | 0.68 |
CPO carriers | 1 (0.7%) | 3 (3.5%) | 0.14 |
CPE carriers | 1 (0.7%) | 3 (3.5%) | 0.14 |
Preemptive contact precautions prescribed | 115 (78.2%) | 70 (81.4%) | 0.45 |
Among all participants screened weekly | n = 589 patientsb | n = 313 patientsb | p value |
---|---|---|---|
Median length of stay (days, IQR)c | 6.9 (2.9–12.6) | 6.9 (3.8–15.1) | 0.06 |
nEcESBL-PE carriers | 19 (3.2%) | 16 (5.1%) | 0.22 |
CPO carriers | 4 (0.7%) | 8 (2.6%) | 0.03 |
CPE carriers | 3 (0.5%) | 3 (1.0%) | 0.42 |
Newly detected carriers | 13 (2.2%) | 10 (3.2%) | 0.52 |
Contact precautions implemented at the time of detection among newly detected carriers | 1/13 (7.7%) | 6/10 (60%) | 0.02 |
Colonization pressure (incidence density) | n = 8884 patient-days | n = 3772 patients-days | p value |
---|---|---|---|
ESBL-PE (cases per 1000 patient-days) | 15.3 [95% CI 12.8–18.1] | 19.1 [95% CI 14.9–24.0] | 0.13 |
CPO (cases per 1000 patient-days) | 0.7 [95% CI 0.2–1.5] | 2.9 [95% CI 1.5–5.2] | 0.05 |
CPE (cases per 1000 patient-days) | 0.4 [95% CI 0.1–1.1] | 1.6 [95% CI 0.6–3.5] | 0.22 |
Antibiotic consumption (ATC JC01) | n = 8884 patient-days | n = 3772 patients-days | p value |
---|---|---|---|
Aminoglycoside (median DDD/1000 patient-days) | 19.2 [95% CI 8.2–26.8] | 22.5 [95% CI 18.3–29.5] | 0.44 |
Carbapenems (median DDD/1000 patient-days) | 97.0 [95% CI 66.9–129.0] | 126.0 [95% CI 104.0–133.0] | 0.18 |
Piperacillin and beta-lactamase inhibitor (median DDD/1000 patient-days) | 145.0 [95% CI 128.0–168.0] | 114.0 [95% CI 96.1–128.0] | 0.03 |
Hand hygiene compliance among healthcare workers | Hand hygiene opportunities = 474 | Hand hygiene opportunities = 360 | p value |
---|---|---|---|
Pooled mean of hand hygiene compliance | 59.7 [95% CI 55.3–64.1] | 61.1 [95% CI 56.1–66.1] | 0.73 |